ACADS/SCAD抗体;ACADS/SCAD Antibody—艾普蒂 新品

+ +

•  

   

     Western blot analysis of ACADS / SCAD expression in HeLa cell lysate.    

  
  

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

•  

   

     Immunoprecipitate (IP) analysis using the Antibody at 1:50 dilution. (wb at 1:1K dilution)    

  
  

ACADS/SCAD antibodies target short-chain acyl-CoA dehydrogenase (SCAD), a mitochondrial enzyme encoded by the *ACADS* gene. SCAD plays a critical role in fatty acid β-oxidation, catalyzing the dehydrogenation of short-chain acyl-CoA derivatives (e.g., butyryl-CoA) to produce energy via the electron transport chain. Deficiencies in SCAD activity, often due to *ACADS* mutations, are linked to SCAD deficiency (SCADD), an autosomal recessive metabolic disorder. SCADD may present with variable symptoms, including hypotonia, developmental delays, and metabolic crises triggered by fasting or illness, though some individuals remain asymptomatic.

ACADS/SCAD antibodies are primarily used in diagnostic and research settings to assess SCAD protein expression and stability. In clinical diagnostics, these antibodies help detect reduced or absent SCAD levels via techniques like Western blot or immunohistochemistry, supporting the confirmation of SCADD alongside genetic testing. Research applications include studying the molecular mechanisms of SCADD, such as misfolding of mutant SCAD proteins or impaired interactions with molecular chaperones. Additionally, these antibodies aid in exploring therapeutic strategies, like chaperone therapy, to stabilize dysfunctional SCAD variants. Their role extends to broader studies on fatty acid metabolism disorders and mitochondrial dysfunction, contributing to understanding genotype-phenotype correlations in SCADD.